HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases sensitivity to TKIs. A total of 82 NSCLC pati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cappuzzo, F, Toschi, L, Domenichini, I, Bartolini, S, Ceresoli, G L, Rossi, E, Ludovini, V, Cancellieri, A, Magrini, E, Bemis, L, Franklin, W A, Crino, L, Bunn, P A, Hirsch, F R, Varella-Garcia, M
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2005
Subjects:	Clinical Study
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2361531/ https://ncbi.nlm.nih.gov/pubmed/16288303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602865
Tags:	Add Tag No Tags, Be the first to tag this record!

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

Similar Items